These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30298281)

  • 1. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.
    Motoi F; Murakami Y; Okada KI; Matsumoto I; Uemura K; Satoi S; Sho M; Honda G; Fukumoto T; Yanagimoto H; Kinoshita S; Kurata M; Aoki S; Mizuma M; Yamaue H; Unno M;
    World J Surg; 2019 Feb; 43(2):634-641. PubMed ID: 30298281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.
    Ariake K; Motoi F; Shimomura H; Mizuma M; Maeda S; Terao C; Tatewaki Y; Ohtsuka H; Fukase K; Masuda K; Hayashi H; Takadate T; Naitoh T; Taki Y; Unno M
    J Gastrointest Surg; 2018 Feb; 22(2):279-287. PubMed ID: 29119533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
    Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
    J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer.
    Takakura Y; Ikeda S; Imaoka Y; Urushihara T; Itamoto T
    Colorectal Dis; 2015 May; 17(5):417-25. PubMed ID: 25512077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.
    Hosokawa Y; Nagakawa Y; Sahara Y; Takishita C; Katsumata K; Tsuchida A
    Dig Surg; 2017; 34(2):125-132. PubMed ID: 27658221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative predictors for early recurrence of resectable pancreatic cancer.
    Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
    World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
    Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
    Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer.
    Takagi C; Kikuchi Y; Shirakawa H; Hoshimoto S; Tomikawa M; Ozawa I; Hishinuma S; Ogata Y
    Anticancer Res; 2019 Jun; 39(6):3177-3183. PubMed ID: 31177164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconsideration about the aggressive surgery for resectable pancreatic cancer: a focus on real pathological portosplenomesenteric venous invasion.
    Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Saisaka Y; Tokumaru T; Iiyama T; Noda Y; Hata Y; Matsumoto M
    Langenbecks Arch Surg; 2015 May; 400(4):487-94. PubMed ID: 25940756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?
    Morita S; Nomura T; Fukushima Y; Morimoto T; Hiraoka N; Shibata N
    Dis Colon Rectum; 2004 Feb; 47(2):227-32. PubMed ID: 15043294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Serum Carbohydrate Antigen 19-9 Concentration Is a Predictor of Survival of Patients Who Have Undergone Curative Resection of Stage IV Rectal Cancer.
    Miki H; Akiyoshi T; Ogura A; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Noma H; Saiura A; Fukunaga Y; Ueno M
    Dig Surg; 2018; 35(5):389-396. PubMed ID: 28858867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.